Valerie Pierce Net Worth

Valerie Pierce biography

Valerie L. Pierce serves as Senior Vice President, Chief Compliance Officer, General Counsel, Secretary of the Company. She brings more than 25 years of experience providing broad legal guidance and leadership to public pharmaceutical and biotechnology companies. She joins NGM from Jazz Pharmaceuticals, where she worked since 2012, most recently as Senior Vice President, Associate General Counsel. Before Jazz, Ms. Pierce worked as Vice President and Senior Transactional Counsel at Amyris, Inc., Senior Vice President and General Counsel at Sunesis Pharmaceuticals, Inc. and in various in-house legal positions at the Institute for OneWorld Health, Tularik Inc. and ALZA Corporation. Ms. Pierce received a B.A. from Yale University and a J.D. from the Yale Law School.

What's Valerie Pierce's mailing address?

Valerie's mailing address filed with the SEC is C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Ngm Biopharmaceuticals Inc

Over the last 5 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel, and Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.

What does Ngm Biopharmaceuticals Inc do?

ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work

Ngm Biopharmaceuticals Inc executives and stock owners

Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:

• David Woodhouse,
  Chief Executive Officer, Director
• Jin-Long Chen,
  Founder, Chief Scientific Officer, Director
• William Rieflin,
  Executive Chairman of the Board of Directors
• Suzanne Hooper,
  Independent Director
• Dr. David J. Woodhouse Ph.D.,
  CEO & Director
• Dr. Jin-Long Chen Ph.D.,
  Founder, Chief Scientific Officer & Director
• Shelly Guyer,
  Independent Director
• Siobhan Nolan Mangini,
  CFO and Principal Financial & Accounting Officer
• McHenry Tichenor,
  Independent Director
• David Goeddel,
  Lead independent director
• David Schnell,
  Independent Director
• Mark Leschly,
  Independent Director
• William J. Rieflin J.D.,
  Exec. Chairman of Directors
• Siobhan Mangini,
  Chief Financial Officer
• Carole Ho,
  Independent Director
• Hsiao Lieu,
  Senior Vice President, Chief Medical Officer
• Marc Learned,
  Vice President - Research Operations
• Hui Tian,
  Senior Vice President - Research
• Wenyan Shen,
  Senior Vice President - Biologics and CMC
• Alex DePaoli,
  Senior Vice President, Chief Translational Officer
• Valerie Pierce,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Dr. Hsiao Dee Lieu,
  Chief Medical Officer & Sr. VP
• Brian Muma,
  VP of HR
• Valerie L. Pierce J.D.,
  Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer
• Alexander Duke Schwartz,
  Exec. Director of Investor Relations
• Group L Ptcg Opportunity Ii...,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L P Svennilson Peter ...,
  
• Peter Svennilson,
  Director
• Group L Pcolumn Group Ii, L...,
  
• Group L Pcolumn Group Iii, ...,
  
• Aetna Wun Trombley,
  President & COO
• Group L Pcolumn Group Ii, L...,
  
• Group L Pcolumn Group Ii, L...,
  
• Group L P Ponoi Capital Ii,...,
  
• Group L Pcolumn Group Iii, ...,
  
• Roger M Perlmutter,
  
• Group L Pcolumn Group Gp, L...,
  
• Group L Pcolumn Group Iii, ...,
  
• Jean Frederic Viret,
  Chief Financial Officer
• Group Gp, Lpcolumn Group Ii...,
  
• Opportunity Iii Gp, Llc Tcg,
  10% owner
• Irene Perlich,
  Principal Accounting Officer